MHR
CORT icon

Matthew Hamilton Rosenberg’s Corcept Therapeutics CORT Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$65 – 868
2023
Q4 		$65 Hold
2
– – ﹤0.01% 893
2023
Q3 		$54 Hold
2
– – ﹤0.01% 909
2023
Q2 		$45 Buy
+2
New +$46 ﹤0.01% 940

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Matthew Hamilton Rosenberg's CORT Position: Q1 2024 in Review

Matthew Hamilton Rosenberg sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 2 shares — an estimated $65 sold.

Matthew Hamilton Rosenberg first reported a position in CORT in Q2 2023 and held it in 3 quarters. The position peaked at $65 in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • Matthew Hamilton Rosenberg reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Matthew Hamilton Rosenberg sold 2 Corcept Therapeutics shares in Q1 2024, an estimated $65.
  • Matthew Hamilton Rosenberg first reported a position in Corcept Therapeutics in Q2 2023 and held it in 3 quarters.
  • Matthew Hamilton Rosenberg's Corcept Therapeutics position peaked at $65 in Q4 2023.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Matthew Hamilton Rosenberg's 13F filing for Q1 2024, filed 22 Apr 2024.